26,196 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Purchased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 26,196 shares of the company's stock, valued at approximately $4,113,000. Thrivent Financial for Lutherans owned 0.08% of TransMedics Group at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in TransMedics Group in the second quarter valued at about $47,000. USA Financial Formulas bought a new position in shares of TransMedics Group during the 3rd quarter worth approximately $55,000. J.Safra Asset Management Corp raised its stake in shares of TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock worth $67,000 after acquiring an additional 383 shares in the last quarter. Signaturefd LLC lifted its position in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company's stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock valued at $76,000 after acquiring an additional 316 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Performance

NASDAQ:TMDX traded up $2.54 during mid-day trading on Monday, hitting $78.58. The company's stock had a trading volume of 1,523,854 shares, compared to its average volume of 993,285. The business's fifty day moving average is $119.18 and its two-hundred day moving average is $137.84. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of 80.89 and a beta of 2.08. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a 1 year low of $67.77 and a 1 year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analysts' expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm's quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.12) EPS. Analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on TMDX shares. Stephens increased their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Needham & Company LLC restated a "hold" rating and set a $109.00 price target on shares of TransMedics Group in a research note on Friday. Baird R W raised shares of TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. JPMorgan Chase & Co. dropped their target price on shares of TransMedics Group from $173.00 to $116.00 and set an "overweight" rating on the stock in a research report on Tuesday, October 29th. Finally, Piper Sandler decreased their price target on shares of TransMedics Group from $180.00 to $110.00 and set an "overweight" rating for the company in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average price target of $131.80.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of the company's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares of the company's stock, valued at approximately $3,089,766.32. This represents a 12.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the firm's stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock valued at $5,230,528 in the last 90 days. 7.00% of the stock is currently owned by company insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.